Why Tyson Stock Is Moving Today

Tyson Foods, Inc. (NYSE: TSN) shares are trading higher.

Tyson Foods, Inc. (NYSE:TSN) shares are trading higher. The company late Friday announced a definitive agreement where Cal-Maine Foods, Inc. (NASDAQ:CALM) would acquire its recently closed facilities.

What To Know: Under the agreement, which was announced last Friday after the close of the market, Cal-Maine Foods will acquire a broiler processing plant, hatchery and feed mill in Dexter, Missouri which the company intends to repurpose for use in egg and egg products production. Cal-Maine Foods also plans to make further investments in the facilities and community.

The company expects that the transaction will close in its third-quarter.

Sherman Miller, President and CEO of Cal-Maine Foods, Inc., said, “We are pleased to announce the proposed acquisition of the assets of Tyson’s former broiler processing facility in Dexter, Missouri.”

“This transaction is consistent with our growth strategy to expand our business through selective acquisitions in addition to our organic growth initiatives. The Dexter location offers an important opportunity to expand our geographic footprint and enhance our ability to serve our valued customers with added production and distribution capabilities in Missouri and surrounding markets.”

Related Link: There’s Optimism Around Longboard Pharmaceuticals’ Anti-Seizure Candidate: Analyst Boosts Price Target

TSN, CALM Price Action: Shares of Tyson Foods were up 3.68% at $55.73 while shares of Cal-Maine Foods were down 2.96% at $55.69 at the time of publication, according to Benzinga Pro.

Image by 9883074 from Pixabay

 

 

Total
0
Shares
Related Posts
Read More

Annexon Announced Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications; Said Well-Capitalized with Operating Runway into 2025

Annexon, Inc. (Nasdaq: ANNX) today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

ANNX